TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+0.75%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.44B
AUM Growth
+$2.44B
(-4%)
Cap. Flow
-$52.5M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$43.6M |
| 2 |
Humana
HUM
|
$23.9M |
| 3 |
Eli Lilly
LLY
|
$20.7M |
| 4 |
Illumina
ILMN
|
$18.9M |
| 5 |
Abbott
ABT
|
$15.8M |
Top Sells
| 1 |
McKesson
MCK
|
$43.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$23.3M |
| 3 |
UnitedHealth
UNH
|
$23M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$21.7M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$19.4M |
Sector Composition
| 1 | Healthcare | 96.9% |
| 2 | Real Estate | 1.86% |
| 3 | Industrials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
McKesson
MCK
$85.4B
| $11.4M | 0.47% | 33,657 -127,065 | -79% | -$43.2M |
|
52
Acadia Healthcare
ACHC
$2.12B
| $11M | 0.45% | 141,189 +68,882 | +95% | +$5.39M |
|
|
BHVN
53
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $10.6M | 0.43% | 70,176 | – | – |
|
54
Novartis
NVS
$245B
| $10.4M | 0.42% | 136,225 | – | – |
|
55
uniQure
QURE
$896M
| $9.79M | 0.4% | 521,693 | – | – |
|
56
Labcorp
LH
$23.1B
| $9.04M | 0.37% | 44,142 | – | – |
|
57
Omega Healthcare
OHI
$12.6B
| $9.04M | 0.37% | 306,433 | – | – |
|
58
Intellia Therapeutics
NTLA
$1.22B
| $8.63M | 0.35% | 154,269 +96,089 | +165% | +$5.38M |
|
|
MRTX
59
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.55M | 0.35% | 122,390 +38,606 | +46% | +$2.7M |
|
|
ITCI
60
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $8.02M | 0.33% | 172,371 -71,066 | -29% | -$3.31M |
|
61
Addus HomeCare
ADUS
$2.12B
| $7.97M | 0.33% | 83,632 | – | – |
|
62
HealthEquity
HQY
$7.72B
| $7.4M | 0.3% | 110,214 -5,100 | -4% | -$343K |
|
|
SGEN
63
DELISTED
Seagen Inc. Common Stock
SGEN
| $7.31M | 0.3% | 53,387 -141,796 | -73% | -$19.4M |
|
64
Ascendis Pharma
ASND
$11.8B
| $7M | 0.29% | 67,794 | – | – |
|
65
Alkermes
ALKS
$4.78B
| $6.91M | 0.28% | 309,613 +119,491 | +63% | +$2.67M |
|
|
LTC
66
LTC Properties
LTC
$1.68B
| $6.83M | 0.28% | 182,293 | – | – |
|
67
Denali Therapeutics
DNLI
$2.23B
| $6.83M | 0.28% | 222,420 | – | – |
|
68
Sabra Healthcare REIT
SBRA
$4.58B
| $6.7M | 0.27% | 510,660 | – | – |
|
69
Elevance Health
ELV
$71.8B
| $6.65M | 0.27% | 14,644 | – | – |
|
|
MDRX
70
DELISTED
Veradigm Inc. Common Stock
MDRX
| $6.53M | 0.27% | +428,580 | New | +$6.53M |
|
71
Travere Therapeutics
TVTX
$1.56B
| $6.1M | 0.25% | 247,678 | – | – |
|
72
Caribou Biosciences
CRBU
$174M
| $5.98M | 0.24% | 567,147 -132,230 | -19% | -$1.39M |
|
73
Owens & Minor
OMI
$378M
| $5.43M | 0.22% | 225,117 -63,050 | -22% | -$1.52M |
|
|
KRTX
74
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.31M | 0.22% | 23,616 -55,441 | -70% | -$12.5M |
|
|
GTHX
75
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $5.29M | 0.22% | 423,869 | – | – |
|